2014
DOI: 10.1002/jps.23854
|View full text |Cite
|
Sign up to set email alerts
|

In Situ Floating Hydrogel for Intravesical Delivery of Adriamycin Without Blocking Urinary Tract

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
42
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 49 publications
(43 citation statements)
references
References 24 publications
1
42
0
Order By: Relevance
“…To mimic the human urinary bladder, an in vitro bladder simulation model was established from slight modifications of an earlier report. 26…”
Section: In Vitro Bladder Simulation Studymentioning
confidence: 99%
“…To mimic the human urinary bladder, an in vitro bladder simulation model was established from slight modifications of an earlier report. 26…”
Section: In Vitro Bladder Simulation Studymentioning
confidence: 99%
“…In this floating hydrogel system, the hydrogel could float immediately due to the whole hydrogel was full of micro-bubbles at the beginning by shaking the P407 solution. However, the time to float of hydrogels we previously developed were several minutes, because chemical reaction took time [7,8]. …”
Section: Discussionmentioning
confidence: 99%
“…As hydrogels attach to the bladder wall, another problem is serious bladder irritation symptoms, such as blood clots in bladder [6]. The two floating hydrogel drug delivery systems we developed before were able to overcome these two shortcomings and prolonged the resident time of drug in the bladder [7,8]. The first floating hydrogel system consisted of thermo-sensitive polymer (Poloxamer 407) and NaHCO 3 , which was liquid at low temperature while forming gel at body temperature (37 °C).…”
Section: Introductionmentioning
confidence: 99%
“…Human studies to characterize the safety, pharmacodynamics, and pharmacokinetics of intraperitoneal P407 have not yet been performed, but animal studies suggest that intraperitoneal injections of P407 have a half life of approximately 21 h based on urinary excretion [28]. P407 is currently Food and Drug Administration-approved for clinical use in vascular anastomosis [4] and is under active preclinical investigation for many additional novel applications [23, 36]. …”
Section: Discussionmentioning
confidence: 99%